Hydroxychloroquine inhalation - APT Pharmaceuticals/Aradigm

Drug Profile

Hydroxychloroquine inhalation - APT Pharmaceuticals/Aradigm

Alternative Names: APT-001; APT-002; APT-003; ARD 1300; HCQ

Latest Information Update: 13 Dec 2010

Price : $50

At a glance

  • Originator APT Pharmaceuticals Inc; Aradigm Corporation
  • Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Sarcoidosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Dec 2010 Discontinued - Phase-II for Asthma in Australia (Inhalation)
  • 13 Dec 2010 Discontinued - Phase-II for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top